RxDoctor Payments Data

Bruce Trippe, MD

Endocrinology, Diabetes & Metabolism · Dothan, ALNPI 1700936200

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Amarin Pharma, Inc. at 32.5% of the total. Reporting peaked in 2019 at $35,441 and has fallen 98.0% since, to $704 in 2025.

$68,065in general payments, 2019–2025

Across 618 payments — averaging $110.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$22K
  • IBSA Pharma Inc.$16K
  • Mannkind Corporation$8K
  • Novo Nordisk$5K
  • Alfasigma USA, Inc.$4K
  • Kowa Pharmaceuticals America, Inc.$3K
  • plus $10K from 38 others
$68,012in research payments, 2019–2025

Across 246 payments — averaging $276.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$68K
  • Janssen Research & Development, LLC$90

What the payments were for

  • Consulting fees$14,68022%
  • Speaking & faculty fees$31,05046%
  • Travel & lodging$10,61316%
  • Food & beverage$11,48117%
  • Education$1810%
  • Gifts$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,065 in reported general payments places this provider in the 85th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.

See all endocrinology, diabetes & metabolism providers in Alabama

Medicare billing

Part B allowed, 2024
$31,978
Medicare patients
95
Services billed
209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AfrezzaInsulin Regular, Human17$68,344
VascepaIcosapent Ethyl89$44,670
MounjaroTirzepatide28$37,204
BaqsimiGlucagon28$14,221
Praluent PenAlirocumab22$13,313
LivaloPitavastatin Calcium22$13,173
JardianceEmpagliflozin15$10,034
EdarbiAzilsartan Medoxomil15$7,169
Colesevelam Hcl14$4,347
Tirosint-SolLevothyroxine Sodium12$3,417
SynthroidLevothyroxine Sodium30$3,202
Icosapent Ethyl18$3,184
Novolog FlexpenInsulin Aspart12$2,589
Insulin Lispro Kwikpen U-100Insulin Lispro11$1,102
Ezetimibe19$454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Mannkind CorporationAfrezza$7,544$68,34417 claims
Lilly USA, LLCMounjaro, Baqsimi$1,586$51,42556 claims
Kowa Pharmaceuticals America, Inc.Livalo$3,431$13,17322 claims
Boehringer IngelheimJardiance$338$10,03415 claims
IBSA Pharma Inc.Tirosint-Sol$16,251$3,41712 claims
AbbVieSynthroid$152$3,20230 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$44$26318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.

Other endocrinology, diabetes & metabolism in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →